Patents by Inventor Zehong Wan

Zehong Wan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
    Publication number: 20230339949
    Abstract: The present invention relates to a heterocyclic substituted fused ?-carboline derivative, a preparation method therefor, an intermediate thereof and use thereof. The heterocyclic substituted fused ?-carboline derivative has a compound structure as represented by formula (I). Such compound can be used for preparing a medicament for treating neuropsychiatric diseases.
    Type: Application
    Filed: October 8, 2021
    Publication date: October 26, 2023
    Inventors: Zehong WAN, Jiaquan FENG, Yongqi WU, Jun QIN, Bingcheng ZHOU, Zhijing HU, Xinjian JIANG, Zijin FENG
  • Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
    Patent number: 10975081
    Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Yun Jin, Qian Liu, Feng Ren, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Hailong Wang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • LRRK2 inhibitors for the treatment of Parkinson's disease
    Patent number: 10618901
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 14, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • COMPOUNDS
    Publication number: 20200079777
    Abstract: Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 22, 2016
    Publication date: March 12, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao DING, Yun JIN, Qian LIU, Feng REN, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Hailong WANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20200055863
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 20, 2020
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Compounds
    Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • COMPOUNDS
    Publication number: 20190023715
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
  • COMPOUNDS
    Publication number: 20180354956
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: August 2, 2018
    Publication date: December 13, 2018
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • Compounds
    Patent number: 10125141
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 13, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Compounds as LRRK2 kinase inhibitors
    Patent number: 10087186
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 2, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao Ding, Luigi Piero Stasi, Zehong Wan, Colin Michael Edge
  • Compounds
    Patent number: 9815841
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: November 14, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao Ding, Qian Liu, Kai Long, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Qiongfeng Xu, Colin Michael Edge
  • Compounds
    Patent number: 9783546
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 10, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang
  • Compounds
    Publication number: 20170204109
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SWNDER, Eric Steven MANAS, Raphael Annthony RIVERO, Joseph e PERO, Christopher ERNST NEIPP, Vipuljumar Kantibhai PATEL
  • COMPOUNDS
    Publication number: 20170204108
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG
  • 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA) inhibitors
    Patent number: 9708330
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Yingxia Sang, Qing Zhang
  • COMPOUNDS
    Publication number: 20170022204
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 28, 2015
    Publication date: January 26, 2017
    Inventors: Xiao DING, Qian LIU, Kai LONG, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Qiongfeng XU, Colin Michael EDGE
  • COMPOUNDS
    Publication number: 20170015668
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 28, 2015
    Publication date: January 19, 2017
    Inventors: Xiao DING, Qian LIU, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Baowei ZHAO, Colin Michael EDGE
  • 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
    Patent number: 9296755
    Abstract: The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: March 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang
  • Substituted pyrimido[1,6-a]pyrimidines as Lp-PLAinhibitors
    Patent number: 9273054
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Kai Long, Xiaomin Zhang, Haihua Yu
  • 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
    Publication number: 20150361082
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Application
    Filed: January 23, 2014
    Publication date: December 17, 2015
    Inventors: Zehong WAN, Yingxia SANG, Qing ZHANG